AUTL is Autolus Therapeutics plc (Healthcare) — a non-dividend-paying stock. Trading at $2.24. Market cap: $596M.
Stock snapshot
| Price | $2.24 |
| Market cap | $596M |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
About AUTL
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Related non-dividend companies
Other non-dividend stocks investors research alongside AUTL. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is AUTL's current stock price?
AUTL (Autolus Therapeutics plc) is currently trading at $2.24.
Does AUTL pay a dividend?
AUTL (Autolus Therapeutics plc) does not currently pay a regular dividend.
Track AUTL in DiviDrip
Add AUTL to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search AUTL and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.